Is Ashwagandha Cognition Meta-Analysis safe?

The current Migaku evidence database contains 2 reusable source documents for Ashwagandha Cognition Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - Methodological quality and risk of bias were assessed with RoB 2, evidence certainty for each outcome was evaluated with GRADE system, and botanical reporting was assessed with the ConPhyMP checklist. [Zhu X (2026); evidence level 1] - Ashwagandha significantly improved memory (SMD = 0.52; 95% CI: 0.27-0.78; P 2 = 29.7%), attention and processing speed (SMD = 0.29; 95% CI: 0.07-0.51; P = 0.009; I 2 = 0%), and executive function (SMD = -0.42; 95% CI: -0.70 to -0.13; P = 0.004; I 2 = 37.5%). [Zhu X (2026); evidence level 1] - Visuospatial ability improved after excluding one heterogeneous study (SMD = 0.39; 95% CI: 0.08-0.70; P = 0.013; I 2 = 0%). [Zhu X (2026); evidence level 1] - Background This study aimed to systematically review and evaluate the effects of Withania somnifera (L.) Dunal (Solanaceae) supplementation on cognitive and physical function in adults by meta-analysis. [Zhu X (2026); evidence level 1] - Many reviews suggest multiple biological activities, often based on preclinical evidence concerning WS. [Pandey Sudip (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.